High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 4, 2012, Pages 468-472

  Satti, Hind ^a,b   Mafukidze, A ^a   Jooste, P L ^c   McLaughlin, M M ^d   Farmer, P E ^a,b,d   Seung, K J ^a,d  

^a PARTNERS IN HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adverse reactions; Multidrug resistant tuberculosis; Thyroid

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; LEVOTHYROXINE; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THYROTROPIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOTHYROIDISM; IODINE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING TEST; THYROTROPIN BLOOD LEVEL; UNITED STATES;

ADULT; ANTITUBERCULAR AGENTS; DRUG MONITORING; FEMALE; HUMANS; HYPOTHYROIDISM; LESOTHO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYROTROPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84858691069     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0615     Document Type: Article

References (26)

1. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011. WHO/HTM/TB/2011.3. Geneva, Switzerland: WHO, 2011.
2. Mukherjee J S, Rich M L, Socci A R, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481. (Pubitemid 38210067)
3. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
4. Schless J M, Allison R F, Inglis R M, White E F, Topperman S. The use of ethionamide in combined drug regimens in the retreatment of isoniazid-resistant pulmonary tuberculosis. Am Rev Respir Dis 1965; 91: 728-737.
5. Gupta D K. Acceptability of thioamides: I. Ethionamide. J Postgrad Med 1977; 23: 175-180.
6. Moulding T, Fraser R. Hypothyroidism related to ethionamide. Am Rev Respir Dis 1970; 101: 90-94.
7. Drucker D, Eggo M C, Salit I E, Burrow G N. Ethionamide-induced goitrous hypothyroidism. Ann Intern Med 1984; 100: 837-839. (Pubitemid 14121595)
8. McDonnell M E, Braverman L E, Bernardo J. Hypothyroidism due to ethionamide. N Engl J Med 2005; 352: 2757-2759.
9. Edwards D A, Rowlands E N, Trotter W R. The mechanism of the goitrogenic action of p-aminosalicylic acid. Lancet 1954; 264: 1051-1052.
10. Munkner T. Studies on goitre due to para-aminosalicylic acid. Scand J Respir Dis 1969; 50: 212-226.
11. Soumakis S A, Berg D, Harris H W. Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis. Clin Infect Dis 1998; 27: 910-911. (Pubitemid 29244363)
12. Seung K J, Omatayo D B, Keshavjee S, Furin J J, Farmer P E, Satti H. Early outcomes of MDR-TB treatment in a high HIV prevalence setting in southern Africa. PLoS ONE 2009; 4: e7186.
13. Pino S, Fang S L, Braverman L E. Ammonium persulfate: a new and safe method for measuring urinary iodine by ammonium persulfate oxidation. Exp Clin Endocrinol Diabetes 1998; 106 (Suppl 3): S22-S27. (Pubitemid 28534910)
14. Delange F, de Benoist B, Burgi H. Determining median urinary iodine concentration that indicates adequate iodine intake at population level. Bull World Health Organ 2002; 80: 633-636.
15. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655. (Pubitemid 32652155)
16. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
17. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384. (Pubitemid 39611587)
18. Shin S, Furin J, Alcantara F, et al. Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. Chest 2004; 125: 974-980. (Pubitemid 38367288)
19. Adler S M, Wartofsky L. The nonthyroidal illness syndrome. Endocrinol Metab Clin North Am 2007; 36: 657-672, vi. (Pubitemid 47135590)
20. Plikat K, Langgartner J, Buettner R, et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism 2007; 56: 239-244. (Pubitemid 46074071)
21. Spencer C, Eigen A, Shen D, et al. Specificity of sensitive assays of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients. Clin Chem 1987; 33: 1391-1396. (Pubitemid 18041977)
22. Hamblin P S, Dyer S A, Mohr V S, et al. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. J Clin Endocrinol Metab 1986; 62: 717-722. (Pubitemid 16138144)
23. Chow C C, Mak T W, Chan C H, Cockram C S. Euthyroid sick syndrome in pulmonary tuberculosis before and after treatment. Ann Clin Biochem 1995; 32 (Pt 4): 385-391.
24. Madeddu G, Spanu A, Chessa F, et al. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study. Clin Endocrinol (Oxf) 2006; 64: 375-383.
25. Sebotsa M L, Dannhauser A, Jooste P L, Joubert G. Prevalence of goitre and urinary iodine status of primary-school children in Lesotho. Bull World Health Organ 2003; 81: 28-34. (Pubitemid 36168650)
26. Sebotsa M L, Dannhauser A, Jooste P L, Joubert G. Iodine status as determined by urinary iodine excretion in Lesotho two years after introducing legislation on universal salt iodization. Nutrition 2005; 21: 20-24. (Pubitemid 40127561)